News

Take a look at 7 major clinical trials to keep an eye on for the upcoming ESC Congress from August 29-September 1, 2025.

Oral supplementation with a novel dietary AGA-P supplement was shown to increase the clinical efficacy of pharmacological treatments for androgenic alopecia.

In a study, ADHD treatments were linked to reduced suicidal behavior, substance misuse, transport accidents, and criminality, but not accidental injuries.

The cross-sectional analysis of NHANES data highlights obesity and overweight’s influence on the development of obesity-related conditions in US youth.

If approved, the investigative therapy could provide a frontline treatment for patients with SAA who do not have matched sibling donors for cell transplantation.

The investigators present pooled findings from the SUNSHINE and SUNRISE trials assessing secukinumab therapy for HS.

An audio recap of the top 5 stories in healthcare news from the week of 08/17-08/

This study highlights a significant link between alopecia areata and autoimmune thyroid disease, assessing a large-scale and diverse population.

Stay updated with the latest healthcare breakthroughs, including FDA news and new cardiology research, in this week's essential news roundup.

In this analysis, investigators looked at quality of life data among pediatric patients with atopic dermatitis in Sub-Saharan Africa.

MGH investigators confirmed the reliability of the Drug Allergy History Tool (DAHT), which outperformed EHR documentation in completeness.

This episode highlights the groundbreaking approval of semaglutide for metabolic dysfunction-associated steatohepatitis, as well as GoodRx’s new Ozempic pricing.

In this analysis, evidence which supports a shift in clinical practice using Chinese herbal medicine was explored for atopic dermatitis.

This episode is the final ADCES 2025 recap episode and includes a spotlight on diabetes technology updates.

In a new study, esketamine nasal spray improved anhedonia in treatment-resistant unipolar and bipolar depression, independent of general symptom changes.

Investigators have cited population growth and epidemiological improvements as leading causes for the significant jump in cases.

Best discussed the landmark approval for zopapogene imadenovec for recurrent respiratory papillomatosis.

This study highlights an approach to male pattern baldness using a topical dimethylglycine sodium salt (DMG-Na) and caffeine-containing shampoo.

Pergola describes the shortcomings of current phosphate binders and what benefits OLC may offer for hyperphosphatemia in patients with CKD on dialysis.

Four allergens not on the FDA or EFSA food allergy list show high frequency in a recent study. Anaphylaxis induced by goat or sheep milk led to 2 deaths.

Preliminary findings have also indicated an association between an evolocumab add-on to statin therapy and stenosis degree reduction.

The FDA has approved Ionis Pharmaceuticals' donidalorsen to prevent HAE attacks in adults and children over 12 years.

With positive topline phase 2 results, parent company Crinetics Pharmaceuticals, Inc., has announced plans to begin phase 3 testing in the second half of 2025.

Targeted C.difficile screening and prophylaxis focused on high-risk immunocompromised patients was linked to reductions in hospital-onset infection.

This cohort study suggests that patients with HS treated with adalimumab have an increased risk of infection compared to those with psoriasis.

A recent study shows combined treatment increases total and N3 sleep in just 3 days for patients with comorbid insomnia and depression.

According to investigators, individuals with 3 or more risk factors for metabolic syndrome have a 40% greater risk of developing Parkinson’s.

Laura Ferris, MD, PhD, reflects on her unexpected path to department chair as well as the lessons of her journey as a leader in academic medicine.